The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00674843
First received: May 6, 2008
Last updated: August 14, 2009
Last verified: August 2009

May 6, 2008
August 14, 2009
May 2008
May 2010   (final data collection date for primary outcome measure)
Management and Cure of muscular dystrophies [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00674843 on ClinicalTrials.gov Archive Site
Rehabilitation of people with muscular dystrophies [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.

The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly cure these neuromuscular disorders.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Muscular Dystrophies
Radiation: Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared radiation
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Intervention: Radiation: Far Infrared Radiation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4
June 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Persons with muscular dystrophies

Exclusion Criteria:

  • None
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00674843
GAAD-MD-CTP1
Yes
Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP